ALL CATEGORIES

Background: MS-CQI is the first multicenter improvement research collaborative for MS. MS-CQI was a three-year study (2018-2020) of variation in outcomes, and leverages benchmarking, site...

Background: Informal unpaid family caregivers (e.g., spouses, parents, siblings) are the primary providers of support to people living with multiple sclerosis (MS), and the experience...

Background: Fatigue is among the most frequent and disabling symptoms in RMS patients. Objectives: To measure multiple sclerosis (MS) fatigue and its impact on daily...

Background: Physical activity may be beneficial for people with multiple sclerosis (MS), but this population is still physically inactive compared to the general public across...

Background: Exercise improves cardiorespiratory and musculoskeletal fitness for people with multiple sclerosis (MS). Recent work suggests that employing a task-oriented approach to exercise, which involves...

Background: Financial barriers to disease modifying therapies (DMT) for multiple sclerosis (MS) have been widely reported; yet the impact of insurance restrictions on DMT choice...

Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for treatment of relapsing remitting (RRMS) and primary progressive multiple sclerosis (PPMS). In the OPERA...

Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for the treatment of relapsing remitting (RRMS) and primary progressive multiple sclerosis (PPMS). During the...

Background: Ocrelizumab (OCR) is a humanized, monoclonal antibody targeting CD20+ B cells and is approved for treatment of relapsing remitting (RRMS) and primary progressive MS...

Background: In patients with multiple sclerosis (MS), adherence and persistence to disease-modifying therapies (DMTs) are important to maintain treatment efficacy. Factors such as dosing schedule...